Qihan Biotech

Executive Summary

Qihan Biotech is a preclinical-stage Chinese biotechnology company pioneering CRISPR gene-edited allogeneic cell therapies and in vivo gene therapies for cancer, autoimmune diseases, and genetic disorders. Founded in 2017 and based in Hangzhou, the company leverages its proprietary gene-editing platform to develop off-the-shelf cell therapies that aim to overcome the limitations of autologous approaches, such as high cost and manufacturing complexity. Its pipeline includes allogeneic CAR-T and CAR-NK candidates targeting hematologic malignancies and solid tumors, as well as in vivo gene editing programs for inherited diseases. Qihan's technology has the potential to deliver durable cures and broaden patient access, positioning it as a key innovator in China's rapidly advancing gene therapy landscape.

Upcoming Catalysts (preview)

• Q4 2026IND filing for lead allogeneic CAR-T candidate60% success
• Q2 2026Presentation of preclinical in vivo gene therapy data at major conference70% success
• H2 2026Strategic partnership or licensing deal for CRISPR platform40% success